What can we help you find?
Regional and state access assistance, improved research and collaboration, and individualized options for patients are key factors in adherence to PrEP.
Health, Bioethics Experts and Advocates Publish Guidance for Research on HIV, Coinfections in Pregnancy
The new report intends to change the practices in the HIV/coinfections research community so that women, providers, and policy makers can make evidence-based decisions regarding the use of medications during pregnancy.
Event-driven PrEP is initiated 2-24 hours ahead of sexual activity, but the most common method of HIV PrEP is a daily oral pill.
Small, automated financial incentives improved retention in care and viral suppression among adults with HIV starting antiretroviral therapy.
Results were announced at the virtual 23rd International AIDS Conference.
In developing countries with overcrowded hospitals, community pharmacies can relive burden, help patients adhere to their regimen, thus offering a viable alternative to patients who need to maintain their medication and keep stable.
PrEP-AP is intended to lower out-of-pocket costs for both uninsured and insured people who are eligible for PrEP services such as laboratory tests.
When taken daily, PrEP is highly effective for preventing HIV from sex or injection drug use.
New research indicates that even with effective antiretroviral treatment, HIV may still affect the central nervous system.
Remdesivir, the investigational drug for the treatment of the coronavirus disease 2019 (COVID-19), will be sold for $390 per vial.
Although researchers know that HIV enters the brain within 8 days of infection, less is known about whether HIV-infected brain cells can release the virus, letting it migrate from the brain back into the body to infect other tissues.
Access and adherence to pre-exposure prophylaxis is vital in eradicating the HIV epidemic in the United States.